# RSV Cases Rise in France as New Immunization Campaigns Roll Out
A surge in respiratory syncytial virus (RSV) detections,coupled with ongoing immunization efforts,is shaping teh landscape of acute respiratory infections in France,according to a recent bulletin released November 5,2025.Health officials are closely monitoring the situation as the nation heads into the winter months, a period traditionally marked by increased respiratory illness.
Increasing RSV Detection Rates
Table of Contents
The detection rate of RSV in nasopharyngeal samples has increased by 6.5 percentage points,reaching 10.8% of samples analyzed in community medicine settings. While the rate remains stable in hospitals at 2.1% – a slight increase of 0.1 percentage point – the rise in community cases signals a broader circulation of the virus. A health agency representative noted that “other viruses likely to induce bronchiolitis, in particular rhinoviruses, are also circulating in France.”
Newborn Immunization Efforts Underway
France is actively implementing a thorough campaign to protect newborns against RSV infections.The initiative, which began in September – and earlier in some overseas territories, including August in Guyana and October in Mayotte – offers two primary strategies: vaccination of pregnant women to provide passive immunity to their infants, or direct immunization of infants under six months with a monoclonal antibody. Details on the program were initially outlined in a dispatch on August 28, 2025.
Expanded RSV Vaccination Recommendations
Beyond newborns, vaccination against RSV is now recommended for individuals aged 75 and over, as well as those aged 65 and over with underlying chronic conditions. These conditions include chronic obstructive pulmonary disease (COPD) and heart failure, where an RSV infection could lead to notable health complications.
Currently available vaccines include mResvia from Moderna,Arexvy from GSK,and Abrysvo from Pfizer.Though, a senior official stated that “none of these vaccines are currently reimbursed by the national healthcare system,” possibly limiting access for some populations. The agency also clarified that the necessity of annual booster shots remains undetermined.
Flu and COVID-19 Trends
While RSV is gaining prominence, other respiratory illnesses are exhibiting different patterns. Influenza activity remains at baseline levels across most of France, with the exception of Mayotte, which entered its pre-epidemic phase the week of October 20. COVID-19 cases are “decreasing in the city and generally stable in the hospital,” suggesting a continued decline in the pandemic’s acute phase.
The health agency will continue to monitor these trends closely and provide updated information as the respiratory illness season progresses.
Why is RSV gaining prominence in France? The rise in RSV detections, notably in community settings, is a key concern as France enters the winter respiratory illness season.The virus is circulating more widely, and the health agency is actively monitoring the situation. Who is most at risk? newborns and older adults with underlying health conditions are particularly vulnerable to severe RSV infections. What is France doing to combat RSV? France has launched a comprehensive immunization campaign offering vaccination to pregnant women and direct immunization to infants. How did the acute phase of the COVID-19 pandemic end? COVID-19 cases are decreasing in urban areas and stabilizing in hospitals, indicating a decline in the pandemic’s acute phase, though monitoring continues.
The health agency will continue to monitor these trends closely and provide updated information as the respiratory illness season progresses.
